Condition: Non Small Cell Lung Cancer Metastatic · ALK Gene Mutation · Sponsor: Centro di Riferimento Oncologico - Aviano
This study aims to evaluate the activity and safety of the combination of platinum-pemetrexed based chemotherapy plus Lorlatinib in ALK positive Non-Small Cell Lung Cancer (NSCLC) with exclusively extracranial disease progression on Lorlatinib. Platinum-pemetrexed based chemotherapy plus Lorlatinib will be administered for an induction phase of four cycles. Subsequently, patients with response or stability of disease at radiological assessment will start the maintenance phase with pemetrexed-Lorlatinib in 21-day cycles until progression, unacceptable toxicity, death, or withdrawal of consent.
This description comes directly from the study's public registry record.
Alessandra Bearz · 0434-659294 · abearz@cro.it
Always discuss trial participation with your own doctor first.
| Centro di Riferimento Oncologico (CRO) IRCCS | Aviano, Italy | Recruiting |
| Azienda Ospedaliero-Universitaria Careggi Oncologia Medica | Florence, Italy | Not Yet Recruiting |
| Azienda USL Toscana Nord Ovest Oncologia Medica, Ospedale Versilia | Lido di Camaiore, Italy | Not Yet Recruiting |
| Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino amadori" | Meldola, Italy | Not Yet Recruiting |
| Fondazione IRCCS San Gerardo dei Tintori | Monza, Italy | Not Yet Recruiting |
| IOV Istituto Oncologico Veneto IRCCS | Padova, Italy | Not Yet Recruiting |
| Azienda Ospedaliero-Universitaria di Parma | Parma, Italy | Not Yet Recruiting |
| Azienda Ospedaliera di Perugia | Perugia, Italy | Not Yet Recruiting |
| Azienda Sanitaria Universitaria Friuli Centrale (ASU FC) | Udine, Italy | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06378892